Monday, February 11, 2013
Japan's biotech stocks have benefited from a spike in interest
from retail investors driven in part by last October's Nobel Prize for a Kyoto
University stem cell researcher. Company executives who spoke with
BioCentury are wary that there could be an equally precipitous outflow -
indeed, there are signs the rally is ebbing - and are mulling raising funds
while the prices are still good.
Since the beginning of the
year, Japanese biotechs have seen their shares rise 71% based on an equal
price-weighted basis (see "Japanese Biotech Performance," A11).